Department of Trauma Surgery, Johann-Wolfgang-Goethe University , Frankfurt/Main, Germany .
Tissue Eng Part C Methods. 2009 Dec;15(4):551-60. doi: 10.1089/ten.TEC.2008.0385.
The size of a bone defect limits the ingrowth of bone-forming cells. Endothelial cell-like differentiated precursor cells (endothelial progenitor cells, EPC) enhance the neovascularization, while marrow stromal cells (MSC) promote the repair of bone defects. Our aim was to evaluate if both types of cells can be cocultivated on a beta-tricalcium phosphate (beta-TCP) matrix and maintain their differentiation capacity as well as to analyze the biologic activity of these cell constructs in vivo.
MSC from human bone marrow and EPC from buffy coat were used. EPC and MSC, alone or in combination, were seeded on fibronectin-coated beta-TCP. After 2, 6, and 10 days the metabolic activity and the endothelial differentiation were tested. On day 10 real-time RT-PCRs for endothelial genes (von Willebrandt factor, vascular endothelial growth factor, and vascular endothelial growth factor-receptor 2), osteogenic genes (osteocalcin, cbfa-1, and collagen-1alpha), and the housekeeping gene glyceraldehyde-3-phosphate dehydrogenase were performed. Cell-containing constructs were implanted into the critical-size defect of the femur of the nude rat. Bone formation and vascularization was determined after 1 week.
MSC and EPC on beta-TCP remain metabolically active over 10 days. They maintain their differentiation as measured by means of Dil-ac-LDL uptake (EPC) and gene expression of lineage typical genes (EPC + MSC). Although a potential osteogenic differentiation of MSC was maybe affected negatively, constructs loaded with MSC resulted in an increase of new bone mass. Constructs containing EPC resulted in an improved vasculogenesis in vivo.
MSC and EPC can be cultivated in combination on a fibronectin-coated beta-TCP, thereby partly maintaining their lineage typical gene expression. The results of the in vivo examinations suggest that beta-TCP combined with EPC and MSC can used as a suitable tool to foster bone healing.
骨缺损的大小限制了成骨细胞的向内生长。内皮细胞样分化前体细胞(内皮祖细胞,EPC)增强了新血管生成,而骨髓基质细胞(MSC)则促进了骨缺损的修复。我们的目的是评估这两种细胞是否可以在β-磷酸三钙(β-TCP)基质上共培养,并保持其分化能力,以及分析这些细胞构建体在体内的生物活性。
使用来自人骨髓的 MSC 和来自白细胞层的 EPC。EPC 和 MSC 单独或组合接种在纤维连接蛋白包被的β-TCP 上。在第 2、6 和 10 天测试代谢活性和内皮分化。在第 10 天,进行实时 RT-PCR 以检测内皮基因(血管假性血友病因子、血管内皮生长因子和血管内皮生长因子受体 2)、成骨基因(骨钙素、cbfa-1 和胶原-1α)和管家基因甘油醛-3-磷酸脱氢酶的表达。将含细胞的构建体植入裸鼠股骨的临界尺寸缺损处。植入后 1 周,测定骨形成和血管化情况。
MSC 和 EPC 在β-TCP 上可在 10 天内保持代谢活性。通过 Dil-ac-LDL 摄取(EPC)和谱系典型基因(EPC+MSC)的基因表达来测量,它们保持其分化。尽管 MSC 的潜在成骨分化可能受到负面影响,但负载 MSC 的构建体导致新骨量增加。含有 EPC 的构建体导致体内血管生成增加。
MSC 和 EPC 可以在纤维连接蛋白包被的β-TCP 上共培养,从而部分保持其谱系典型基因表达。体内检查结果表明,β-TCP 结合 EPC 和 MSC 可作为促进骨愈合的合适工具。